Magicell-NK contains NK cells suspended in not checked
Medigen Biotechnology Corporation
FollowEvery change as it happens, and a Monday email
Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Eligible subjects will be assigned into one of the three dose escalating cohorts (3+3 subjects/cohort) according to the time sequence enrolled”In the company’s words, NCT05394714 on ClinicalTrials.gov
- Tested for
- Colon Cancer Stage I
- Main trialPhase 1
- “This is a Phase I, open-label study to explore the safety profile and to find the maximum tolerated dose (MTD) or maximum feasible dose (MFD) of Magicell-NK in subjects diagnosed with stage I or stage IIa colon cancer post resection from a single site in Taiwan. During this study, 3 dose levels of Magicell-NK will be tested with a 3+3 design to determine the MTD/MFD: Cohort 1, low dose (2×10\^8 cells), Cohort 2, middle dose (6×10\^8 cells), and Cohort 3, high dose (12\~18 ×10\^8 cells).”In the company’s words, NCT05394714 on ClinicalTrials.gov
Other drugs for Colon Cancer Stage I
- DostarlimabGSK · Phase 3
- NuvastaticNatureceuticals Sdn Bhd · Phase 3
- XLJDOD compound granuleJiangsu Famous Medical Technology Co., Ltd. · Phase 3
- RC148RemeGen · AbbVie · Phase 2/3
- INCA33890Incyte Corporation · Phase 3
- CalderasibMerck & Co. · Phase 3
Coming up1
- 30 Jun 2028Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 30 Jun 2028 | A Phase I, Autologous ex Vivo Expanded and Activated NK Cell, Magicell-NK, Infusion for Colon Cancer Post Resection Study |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026